Peptide library / Hormones & metabolism / Degarelix
Degarelix
A GnRH antagonist for advanced prostate cancer that lowers testosterone without an initial surge.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Advanced prostate cancerFDA approved
How it is thought to work
Degarelix blocks GnRH receptors directly, so testosterone falls within days instead of rising first.
What the evidence shows
A phase 3 trial showed castration-level testosterone suppression comparable to leuprolide, with a faster onset.
Safety and unknowns
Injection site reactions are common, along with hot flushes and weight gain.
Regulatory status
FDA-approved as Firmagon in 2008.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Hormones & metabolism
Desmopressin
FDA-approvedA synthetic vasopressin analog that reduces urine production.
Etelcalcetide
FDA-approvedAn injected calcimimetic peptide for high parathyroid hormone in people on dialysis.
Dasiglucagon
FDA-approvedA stable glucagon analog that does not need to be mixed before use.
General information, not medical advice. Do not buy or inject unregulated peptides.